Exploiting temporal aspects of cancer immunotherapy

被引:8
|
作者
Zemek, Rachael M. [1 ,2 ]
Anagnostou, Valsamo [3 ]
Pires da Silva, Ines [4 ,5 ,6 ,7 ]
Long, Georgina V. [4 ,5 ,6 ,8 ]
Lesterhuis, Willem Joost [1 ]
机构
[1] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia
[2] Fred Hutchinson Canc Ctr, Vaccine & Infect Dis Div, Seattle, WA USA
[3] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[5] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia
[6] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia
[7] Blacktown Hosp, Crown Princess Mary Canc Ctr, Sydney, NSW, Australia
[8] Royal North Shore & Mater Hosp, Sydney, NSW, Australia
基金
英国医学研究理事会; 澳大利亚国家健康与医学研究理事会;
关键词
IMMUNE CHECKPOINT BLOCKADE; STAGE-III MELANOMA; CELL LUNG-CANCER; PD-1; BLOCKADE; T-CELLS; TUMOR MICROENVIRONMENT; LYMPHOID STRUCTURES; BRAF INHIBITION; B-CELLS; ANTITUMOR IMMUNITY;
D O I
10.1038/s41568-024-00699-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Many mechanisms underlying an effective immunotherapy-induced antitumour response are transient and critically time dependent. This is equally true for several immunological events in the tumour microenvironment induced by other cancer treatments. Immune checkpoint therapy (ICT) has proven to be very effective in the treatment of some cancers, but unfortunately, with many cancer types, most patients do not experience a benefit. To improve outcomes, a multitude of clinical trials are testing combinations of ICT with various other treatment modalities. Ideally, those combination treatments should take time-dependent immunological events into account. Recent studies have started to map the dynamic cellular and molecular changes that occur during treatment with ICT, in the tumour and systemically. Here, we overlay the dynamic ICT response with the therapeutic response following surgery, radiotherapy, chemotherapy and targeted therapies. We propose that by combining treatments in a time-conscious manner, we may optimally exploit the interactions between the individual therapies. The tumour immune microenvironment greatly affects responses to immune checkpoint therapies. In this Perspective, Zemek et al. explore the dynamic changes in response to both immunotherapy and conventional treatment and advocate for strategic combination therapies over time to enhance antitumour immune responses.
引用
收藏
页码:480 / 497
页数:18
相关论文
共 50 条
  • [1] Exploiting the immunomodulatory properties of chemotherapeutic drugs to improve the success of cancer immunotherapy
    Kersten, Kelly
    Salvagno, Camilla
    de Visser, Karin E.
    FRONTIERS IN IMMUNOLOGY, 2015, 6
  • [2] Cancer immunotherapy: exploiting neoepitopes
    Platten, Michael
    Offringa, Rienk
    CELL RESEARCH, 2015, 25 (08) : 887 - 888
  • [3] The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy
    Verdegaal, Els M. E.
    van der Burg, Sjoerd H.
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [4] Perspectives for immunotherapy in endocrine cancer
    Latteyer, S.
    Tiedje, V.
    Schilling, B.
    Fuehrer, D.
    ENDOCRINE-RELATED CANCER, 2016, 23 (10) : R469 - R484
  • [5] Breast cancer resistance mechanisms: challenges to immunotherapy
    Hanna, Ann
    Balko, Justin M.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (01) : 5 - 17
  • [6] The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy
    Yau, Helen Loo
    Ettayebi, Ilias
    De Carvalho, Daniel D.
    TRENDS IN CELL BIOLOGY, 2019, 29 (01) : 31 - 43
  • [7] Mechanisms of Cancer Resistance to Immunotherapy
    Bai, Rilan
    Chen, Naifei
    Li, Lingyu
    Du, Nawen
    Bai, Ling
    Lv, Zheng
    Tian, Huimin
    Cui, Jiuwei
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [8] Checkpoint inhibitor immunotherapy in kidney cancer
    Xu, Wenxin
    Atkins, Michael B.
    McDermott, David F.
    NATURE REVIEWS UROLOGY, 2020, 17 (03) : 137 - 150
  • [9] Clinical cancer immunotherapy: Current progress and prospects
    Liu, Chenglong
    Yang, Mengxuan
    Zhang, Daizhou
    Chen, Ming
    Zhu, Di
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [10] Application of immune repertoire sequencing in cancer immunotherapy
    Zhuang, Yuan
    Zhang, Changzheng
    Wu, Qiong
    Zhang, Jing
    Ye, Zhenlong
    Qian, Qijun
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 74